A., Wang, S., Andrikopoulos, S
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
Moreover, although ferroptosis leads to pathological changes such as inflammation and ERS, in many cases, they actually interact with each other
Enhanced motor capacity was noted in all subjects in a progressive manner that reaches a plateau during the first 3 months of the study
In summer, days are 15 hours long and in winter only 9 hours of daylight